PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40156118,Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma.,2025-Mar-10,Joel Randolph Hecht; Arjun Oberoi; Elena Garralda Cabanas; Hong Jae Chon; Antonia Digklia; Sylvie Rottey; Miguel Martin Jimenez; Marya Chaney; Jane Hippenmeyer; Tatiana Lawrence; Kate Liu; Ali Hamidi; Jason Chesney,"Merck & Co., Inc., Rahway, NJ 07065, United States.",N/A
40155531,Cytokine biomarkers for independent prediction of hepatocellular carcinoma prognosis.,2025-Mar-29,Long-Bin Jeng; Fu-Ying Shih; Wen-Ling Chan; Chiao-Fang Teng,"Ph.D. Program for Biotech Pharmaceutical Industry, China Medical University, Taichung, 404, Taiwan.",chiaofangteng@gmail.com; chiaofangteng@gmail.com; chiaofangteng@gmail.com
